Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib versus best available therapy for corticosteroid-refractory acute graft-versus-host disease
2016-002584-33Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in corticosteroid-refractory acute graft-versus-host disease (SR-aGVHD) and Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Novartis. Primary endpoint: Overall Response Rate. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
corticosteroid-refractory acute graft-versus-host disease (SR-aGVHD)Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2016-002584-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002584-33.